Navigation Links
Verenium Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012
Date:3/27/2013

turing expenses and the gain on sale to DSM of $31.3 million, the Company's non-GAAP pro-forma loss from operations was $9.6 million for the year ended December 31, 2012 compared to $3.2 million for the prior year.  The Company believes that excluding the impact of these items provides a more consistent measure of operating results.

Net Income (Loss) from Continuing Operations

Net income from continuing operations for the year ended December 31, 2012 was $18.3 million compared to $5.6 million for the prior year, on a GAAP accounting basis. Adjusted for the impact of restructuring expenses, non-cash items related to the change in fair value of derivative assets and liabilities and gain on the sale to DSM, the Company's non-GAAP pro-forma net loss from continuing operations for the year ended December 31, 2012 increased to $12.2 million compared to $6.3 million for the prior year primarily due to a decrease in product and contract manufacturing gross profit and continued research and development investment in pipeline products. The Company believes that excluding the impact of these items provides a more consistent measure of operating results. 

Balance Sheet

The Company ended the quarter with $34.9 million in cash and cash equivalents and $2.5 million in total restricted cash.  On December 7, 2012 the Company entered into a $22.5 million secured debt financing with Athyrium Opportunities Fund ("Athyrium"). Net proceeds after estimated expenses were approximately $21.3 million. The debt bears interest at 11.5% per annum, with interest payments due quarterly over a five-year term and the principal balance due as a lump-sum payment at maturity in December 2017.

"We had a strong fourth quarter, and overall, we are pleased with our financial results for 2012," said Jeff Black, Chief Financial Officer at Verenium. "Importantly, we secured the necessary financing that should enable us to execute on
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Verenium Announces Preliminary Financial Results For Fiscal 2012
2. Verenium To Present At The 25Th Annual Roth Conference
3. Verenium Appoints Holger Liepmann To Its Board Of Directors
4. Verenium To Sponsor The Renewable Fuels Association 18th Annual National Ethanol Conference
5. Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition
6. Verenium Announces $22.5 Million, Five-Year Secured Financing
7. Verenium Corporation To Announce Third Quarter 2012 Financial Results
8. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
11. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
(Date:9/18/2014)... 18, 2014 OMICS Group International ... to participate in the ‘Open Access Week’ by ... OMICS Group Pharma Journals from 20-26th ... the fastest emerging Sciences, accelerating with a tremendous ... across the globe. The industry is gearing with ...
(Date:9/18/2014)... is a group of rare diseases that afflict ... Its onset hits at the fetal stage and ... the gene encoding fibroblast growth factor receptor 3 ... skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia ... is often lethal, and achondroplasia (ACH), which causes ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Israel and NEW YORK, October 2 ... on,Company,s Diagnostic and Therapeutic Development Programs, as Well ... (Nasdaq: ROSG ), a global leader in,microRNA-based ... R&D Day on microRNAs and their significant potential ...
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a ... of technologies targeting the chronic inflammation,underlying cardiovascular and ... close of the North American financial markets,on Tuesday, ... web cast will also,be conducted on Tuesday, October ...
... 2 Othera Pharmaceuticals, Inc., a,specialty pharmaceuticals ... oncology, and inflammatory disease, has,announced the appointment ... Chief,Scientific Officer effective immediately. In this position, ... execution of Othera,s research,and clinical development programs. ...
Cached Biology Technology:Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 2Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 3Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 4Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 2Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 4Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 2Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 3
(Date:9/18/2014)... and their colleagues have built the first smartphone ... performance and behavioral trends. In other words, your ... if you don,t -- and how that affects ... happiness, stress, depression and loneliness to their academic ... population for example, to monitor mental health, ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2
... can counteract the effects of tumor-promoting molecules in skin ... University of Pennsylvania School of Medicine. Using animal models, ... in epithelial cells, preventing uncontrolled cell growth caused by ... published online in the Journal of Biological Chemistry, suggests ...
... suffering chronic obstructive pulmonary disease (COPD) attempt to ... contradicts the conventional wisdom on the capabilities of ... attempted regional elastic fiber repair in severe emphysema," ... Patterson and Richard Pierce of Washington University, St. ...
... neurons may have been a key factor in why ... primate relatives. In a study comparing the genomes of ... U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley ... high degree of genetic differences in DNA sequences that ...
Cached Biology News:Signal protein shows promise for blocking tumor promoters in skin cells 2Lungs try to repair damaged elastic fibers 2Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
Biology Products: